Navigation Links
Stent for life initiative
Date:9/1/2009

Barcelona, Spain, 1 September: Primary angioplasty (with stent implantation) is the most effective therapy for acute myocardial infarction (AMI), but it is not available to many patients, even though most European countries have sufficient resources (ie, catheterisation laboratories) for its wider use. The Stents 4 Life initiative was a study aiming to analyze the use of primary angioplasty in the treatment of AMI in 27 European countries.

Data were collected from national infarction or angioplasty registries, on AMI epidemiology and treatment and on angioplasty centres and procedures in each country.

Findings showed that the frequency (annual incidence) of hospital admission for any AMI varied between 90 and 312 events per 100,000 population per year; the incidence of serious AMIs (with ST-elevations on ECG - STEMI) ranging from 44-142 per thousand.

Primary angioplasty (primary PCI) was the dominant reperfusion strategy in 17 countries and thrombolysis in nine countries. The application of a PCI strategy varied between 5 and 92% (in all STEMI patients), and use of thrombolysis (an older, less effective form of therapy) between 0 and 55%. Curent guidelines recopmmend that any reperfusion treatment (angioplasty or thrombolysis) should be used ideally in 100% of these patients; however, we found it used only in 37󈟉% of STEMI patients.

The number of primary angioplasty procedures per million population per year varied among countries between 20 and 970. The mean population served by a single primary angioplasty centre varied between 0.3 and 7.4 million inhabitants. In those coutries offering primary angioplasty services to most of their STEMI patients, population varied between 0.3 and 1.1 million per centre.

In-hospital mortality of all consecutive STEMI patients varied between 4.2 and 13.5%, of patients treated by thrombolysis between 3.5 and 14%, and of patients treated by primary PCI between 2.7 and 8%.<
'/>"/>

Contact: Jacquelline Partarrieu
jpartarrieu@escardio.org
0034-600-919-617
European Society of Cardiology
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Abbott Launches Next-Generation XIENCE PRIME(TM) Drug Eluting Stent in International Markets
2. Adding a Stent May Help Resolve Brain Aneurysm
3. Health Canada Approves Abbotts XIENCE V(R) Drug Eluting Stent
4. Stenting a Good Option for Left Main Heart Artery
5. Stent Studies Tied to Rapid Changes in Use
6. QHR Client Hospitals Lauded for Consistently High Quality Standards, Exceeding Patient Expectations
7. FDA Approves Boston Scientifics TAXUS(R) Liberte(R) Long Stent
8. AbbeyMoor Medical Receives FDA Approval for Design Improvements to The Spanner(TM) Prostatic Stent
9. CorNova(R) Receives CE Mark Approval for Valecor Platinum(R) Coronary Stent System
10. Abbott Receives CE Mark for Companys Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Advancing Leadership Position
11. Newest Coated Stent Does Well in Real-World Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... For its December issue , Atlantic ... on Blue Cross and Blue Shield Plans* interviewed officials ... strategies the two Blues plans are implementing in order ... sleep apnea, ranging from brick-and-mortar retail stores to patient ... increased rates of a variety of serious disorders, including ...
(Date:11/26/2014)... Howell, NJ (PRWEB) November 26, 2014 ... issues,” and Florida-based SeniorNet, a nonprofit organization providing the ... have teamed up to help seniors navigate the rough ... will focus on educating seniors on the topic of ... through the somewhat complicated process of applying for this ...
(Date:11/26/2014)... Angeles, California (PRWEB) November 26, 2014 ... score of 3.9 out of 5. This score represents ... over the three years to 2014 as a result ... for medical suction machines, which are largely considered nondiscretionary. ... the purchasing process, buyers have some degree of flexibility, ...
(Date:11/26/2014)... Sonoran Vein and Endovascular nurse, ... Distinguished Preceptorship Award from The American Association ... the advancement of nurse practitioners. The Distinguished Preceptorship ... had made a significant contribution toward increasing the ... of Nurse Practitioners (AANP) is the largest full-service ...
(Date:11/26/2014)... 25, 2014 (HealthDay News) -- The number of emergency department ... in 2010 to a record 136 million in 2011, according ... The findings also showed that fewer people were going to ... identified as needing medical care within two hours of arriving ... according to the research. Sixty percent of patients arrived ...
Breaking Medicine News(10 mins):Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 3Health News:Senior Planning Services Teams Up with SeniorNet To Educate Seniors On Medicaid Planning 2Health News:Medical Suction & Vacuum Products Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Medical Suction & Vacuum Products Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Medical Suction & Vacuum Products Procurement Category Market Research Report from IBISWorld has Been Updated 4Health News:Sonoran Nurse Receives Distinguished Preceptorship Award from The American Association of Nurse Practitioners 2Health News:ER Visits on the Rise, Study Reports 2
... Nov. 12 You,re visiting the dentist for what you ... she says you need a root canal. Though it,s a ... in the chair, you may have several questions and feel ... root canals for quite some time. The Pennsylvania Dental Association ...
... Healthcare is an industry faced with unprecedented uncertainty. ... overcome the noise and clearly communicate relevant and timely ... company Griffin York & Krause (GY&K) reaffirmed its commitment ... been honored with six national CardioVascular Advertising (CVA) Awards. ...
... certification pilot significantly expands chemical emissions and content ... from products used in multiple environments. ... (GEI) announces the launch of GREENGUARD Premier(SM), a ... indoor air quality criteria, additional chemical emission requirements ...
... 12 /PRNewswire-FirstCall/ -- Mesa Laboratories, Inc. (Nasdaq: ... declared a regular quarterly dividend of $.11 per share of ... The dividend will be payable December 15, 2009, to shareholders ... in 1984 Mesa Labs has maintained strong cash positions and ...
... Christiana Care Health System,s Helen F. Graham ... nation to submit specimens to the Biospecimen Core Resource ... project is part of a sweeping initiative by the ... and even prevent cancer in the future. , ...
... holds hope of better treatment for muscular dystrophy, ... Researchers are reporting that injections of genes into the ... size and strength without side effects. , The ... gene-therapy findings, though preliminary, might someday lead to better ...
Cached Medicine News:Health News:Painful Root Canals Are a Thing of the Past 2Health News:Healthcare Organizations Face Tough Marketing Challenges - GY&K Asks 'Are You Relevant?' 2Health News:Healthcare Organizations Face Tough Marketing Challenges - GY&K Asks 'Are You Relevant?' 3Health News:GREENGUARD Launches Comprehensive Health-Based Certification Pilot Program 2Health News:Christiana Care First Community Hospital to Submit Samples to Cancer Genome Atlas Project 2
(Date:11/24/2014)... MONTREAL , Nov. 24, 2014 /PRNewswire/ - Milestone ... clinical trial conducted in Melbourne, Australia ... antagonist for the potential treatment of paroxysmal supraventricular ... formulation of MSP-2017 was well tolerated at single ... an excellent safety profile, desirable PK properties including ...
(Date:11/24/2014)... YORK , Nov. 24, 2014  Relmada Therapeutics, ... for the treatment of chronic pain, announced today that ... to present at the LD MICRO "MAIN Event" Micro-Cap ... will be held at the Luxe Sunset Bel Air ... Los Angeles, California . ...
(Date:11/24/2014)... , Nov. 24, 2014  Surgical Theater, LLC, announced ... November 24 th opening of Europe,s ... Neurologico Nazionale "C. Besta." The SuRgical Planner (SRP) and ... at the event for their 3D navigation and augmented ... Joshua Bederson , Professor and Chair, Department of Neurosurgery ...
Breaking Medicine Technology:Milestone Announces Positive Phase 1 Data for MSP-2017; Supports Advancement into Phase 2 in PSVT Patients 2Milestone Announces Positive Phase 1 Data for MSP-2017; Supports Advancement into Phase 2 in PSVT Patients 3Relmada Therapeutics To Present At LD MICRO Conference 2Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 2Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 3
... Biogen Idec (NASDAQ: BIIB),and Elan Corporation, plc (NYSE: ... Prescribing Program(TM) and TYGRIS safety study,confirm the safety ... presented at the 59th annual meeting,of the American ... data that showed that TYSABRI has a sustained ...
... WIRE)--May 3, 2007 - Insmed Inc.,(Nasdaq:INSM) today announced ... the company's drug, IPLEX(TM), in,patients with myotonic muscular ... being conducted at,the University of Rochester School of ... with doses of IPLEX up to 1,mg/kg/day in ...
Cached Medicine Technology:Data Presented at the American Academy of Neurology's Annual,Meeting Provide Update on Utilization and Safety of Tysabri in,Patients with Multiple Sclerosis 2Data Presented at the American Academy of Neurology's Annual,Meeting Provide Update on Utilization and Safety of Tysabri in,Patients with Multiple Sclerosis 3Data Presented at the American Academy of Neurology's Annual,Meeting Provide Update on Utilization and Safety of Tysabri in,Patients with Multiple Sclerosis 4Data Presented at the American Academy of Neurology's Annual,Meeting Provide Update on Utilization and Safety of Tysabri in,Patients with Multiple Sclerosis 5Data Presented at the American Academy of Neurology's Annual,Meeting Provide Update on Utilization and Safety of Tysabri in,Patients with Multiple Sclerosis 6Insmed Announces Promising Results From IPLEX Phase II Myotonic,Muscular Dystrophy Clinical Study 2Insmed Announces Promising Results From IPLEX Phase II Myotonic,Muscular Dystrophy Clinical Study 3Insmed Announces Promising Results From IPLEX Phase II Myotonic,Muscular Dystrophy Clinical Study 4
The Lang Stereotest was created to simplify stereopsis screening in children. It is based on two principles: random dots and cylindrical gratings. The Lang Stereotest I measures disparities: Star 600...
8 X 1 Red Filter. Color Filters are designed to filter out all other color regions of the visible spectrum except the specified color. Color Filters are excellent for contrast enhancement and color r...
Maxi-Lite diagnostic penlight features a twist-on backswitch....
Features a twist-on backswitch with a diffused, cobalt blue, light beam. Packaged with fluorescein strips....
Medicine Products: